This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Preoperative Versus Postoperative Start With Thromboprophylaxis in THA (Total Hip Arthroplasty)

This study has been completed.
Sponsor:
Collaborator:
Oslo University Hospital
Information provided by (Responsible Party):
Pål Borgen, MD, Martina Hansen's Hospital
ClinicalTrials.gov Identifier:
NCT01714297
First received: October 23, 2012
Last updated: December 7, 2012
Last verified: December 2012
  Purpose
The purpose of this study is to determine if there are differences in clinical events, i.e bleeding with associated morbidity, if thromboprophylaxis with LMWH (Low Molecular Weight Heparin) is initiated before or after surgery.

Condition Intervention Phase
Arthritis of the Hip Transfusion Related Complications Infection Wound Discharge Drug: dalteparin 5000 IU s.c. Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A Prospective Randomized, Double Blind Study to Evaluate Safety and Effect With Pre Versus Postoperative Start of Thromboprophylaxis With Dalteparin

Further study details as provided by Pål Borgen, MD, Martina Hansen's Hospital:

Primary Outcome Measures:
  • total blood loss [ Time Frame: during and after surgery ]
    measured blood loss during surgery and in wound drains


Secondary Outcome Measures:
  • transfusion requirements [ Time Frame: during and after surgery ]
    number of units packed red blood cells

  • incidence of bleeding events [ Time Frame: during and after surgery ]
    excessive bleeding, wound hematoma, wound secretion, other bleeding events

  • other complications [ Time Frame: during and after surgery ]
    all other complications related to surgery


Enrollment: 80
Study Start Date: January 2008
Study Completion Date: April 2009
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: dalteparin 5000IU s.c.
5000IU dalteparin s.c. injected the evening before cemented total hip arthroplasty
Drug: dalteparin 5000 IU s.c.
All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
Other Name: Fragmin
Placebo Comparator: saline
Syringes of Saline with the same volume as in the dalteparin injections are injected the evenings before total hip arthroplasty. Dalteparin 5000IU are injected 6 hours after surgery and the concomitant 33 days
Drug: dalteparin 5000 IU s.c.
All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
Other Name: Fragmin

  Eligibility

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

-patients 50 years or older undergoing cemented total hip arthroplasty for primary osteoarthritis

Exclusion Criteria:

  • allergy to Low-Molecular-Weight -Heparin
  • bleeding disorders
  • renal failure
  • hepatic disease
  • active treatment for malignancy
  • history of deep venous thrombosis or pulmonary embolism
  • major operations,trauma,stroke or cardiac infarction the last 3 months before surgery.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01714297

Locations
Norway
Martina Hansen's Hospital
Sandvika, Gjettum, Norway, 1346
Sponsors and Collaborators
Martina Hansen's Hospital
Oslo University Hospital
Investigators
Study Chair: Olav Reikeras, MD, Phd Oslo University Hospital
  More Information

Publications:
Responsible Party: Pål Borgen, MD, MD., Martina Hansen's Hospital
ClinicalTrials.gov Identifier: NCT01714297     History of Changes
Other Study ID Numbers: REK Sør-øst s-08012d
Study First Received: October 23, 2012
Last Updated: December 7, 2012

Keywords provided by Pål Borgen, MD, Martina Hansen's Hospital:
cemented total hip arthroplasty
blood loss
wound discharge
thromboprophylaxis
biomarkers

Additional relevant MeSH terms:
Dalteparin
Heparin, Low-Molecular-Weight
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 23, 2017